Clinical Trial Detail

NCT ID NCT03043313
Title Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Seattle Genetics, Inc.
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Trastuzumab + Tucatinib

Tucatinib

Age Groups: adult senior

Additional content available in CKB BOOST